Crinetics Pharmaceuticals CRNX Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's operating lease right-of-use assets in other assets?
- Crinetics Pharmaceuticals (CRNX) reported operating lease right-of-use assets in other assets of $39.79M in Q1 2026.
- How has Crinetics Pharmaceuticals's operating lease right-of-use assets in other assets changed year-over-year?
- Crinetics Pharmaceuticals's operating lease right-of-use assets in other assets decreased by 6.8% year-over-year, from $42.69M to $39.79M.
- What is the long-term trend for Crinetics Pharmaceuticals's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's operating lease right-of-use assets in other assets has grown at a 78.5% compound annual growth rate (CAGR), from $2.23M to $40.49M.